Jun 25 |
Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer
|
Jun 5 |
Immutep slips after stock offering
|
Jun 5 |
Immutep successfully completes institutional placement and institutional component of entitlement offer
|
Jun 3 |
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
|
May 29 |
Immutep's (ASX:IMM) investors will be pleased with their notable 73% return over the last five years
|
May 15 |
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024
|
May 2 |
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
|
May 1 |
Immutep: Realizing The Expected Catalysts, With More To Come
|
Apr 29 |
Immutep Quarterly Activities Report Q3 FY24
|
Apr 24 |
Immutep reports promising efti/Keytruda data for head and neck cancer
|